Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Intellia Therapeutics stock (NTLA)

Buy Intellia Therapeutics stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Intellia Therapeutics is a biotechnology business based in the US. Intellia Therapeutics shares (NTLA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $16.34 – a decrease of 22.49% over the previous week. Intellia Therapeutics employs 526 staff and has a trailing 12-month revenue of around $46 million.

Our top picks for where to buy Intellia Therapeutics stock

Top pick for advanced traders

Go to site
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Our pick for investing by theme

Go to site
  • Trade $0 commission stocks & ETFs with as little as $1
  • Theme and ETF screener
  • Discover new opportunities with Opto's AI-driven classification system

Our pick for transfer bonus

Go to site
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options, with no options contract fees
  • Complimentary access to a financial planner and automated investing

How to buy Intellia Therapeutics stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – NTLA. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Intellia Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 4 of 4
Name Product USFST Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Tastytrade
Finder Score: 4.4 / 5: ★★★★★
Tastytrade
★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
$0
$0
N/A
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
OPTO
Finder Score: 3.1 / 5: ★★★★★
OPTO
★★★★★
Stocks, ETFs
$0
$0
N/A
Earn up to $300
AI-driven thematic investing, with proprietary research, fractional shares and commission-free stocks and ETFs.
SoFi Invest®
Finder Score: 4.2 / 5: ★★★★★
SoFi Invest®
★★★★★
Stocks, Options, Mutual funds, ETFs, Alternatives
$0
$0
0.02%
Get up to $1,000 in stock
Zero-commission stocks, ETFs and options, with no options per-contract fees. Plus, a no-advisory-fee robo-advisor and complimentary access to financial planners.
Robinhood
Finder Score: 4.5 / 5: ★★★★★
Robinhood
★★★★★
Stocks, Options, ETFs, Cryptocurrency
$0
$0
4.5%
Get a free stock
Trade stocks, options, ETFs and crypto without commissions and on a user-friendly platform. Plus, a 1% IRA match and no options contract fees.
loading

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Intellia Therapeutics stock price (NASDAQ: NTLA)

Use our graph to track the performance of NTLA stocks over time.

Intellia Therapeutics shares at a glance

Information last updated 2024-10-25.
Latest market close$16.34
52-week range$15.35 - $34.87
50-day moving average $20.85
200-day moving average $24.17
Wall St. target price$66.13
PE ratio N/A
Dividend yield N/A
Earnings per share (TTM) $-5.48

Is it a good time to buy Intellia Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Intellia Therapeutics price performance over time

Historical closes compared with the close of $15.95 from 2024-10-25

1 week (2024-10-22) -24.34%
1 month (2024-09-27) -24.05%
3 months (2024-07-29) -40.79%
6 months (2024-04-29) -27.43%
1 year (2023-10-27) -31.13%
2 years (2022-10-28) -70.48%
3 years (2021-10-29) 132.98
5 years (2019-10-29) 41.78%

Intellia Therapeutics financials

Revenue TTM $46 million
Gross profit TTM $-367,858,000
Return on assets TTM -26.05%
Return on equity TTM -49.02%
Profit margin 0%
Book value $9.88
Market Capitalization $2 billion

TTM: trailing 12 months

Intellia Therapeutics share dividends

We're not expecting Intellia Therapeutics to pay a dividend over the next 12 months.

Intellia Therapeutics share price volatility

Over the last 12 months, Intellia Therapeutics's shares have ranged in value from as little as $15.35 up to $34.87. A popular way to gauge a stock's volatility is its "beta".

NTLA.US volatility(beta: 1.76)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Intellia Therapeutics's is 1.759. This would suggest that Intellia Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Intellia Therapeutics overview

Intellia Therapeutics, Inc. , a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc.

Frequently asked questions

null
What percentage of Intellia Therapeutics is owned by insiders or institutions?
Currently 1.209% of Intellia Therapeutics shares are held by insiders and 87.415% by institutions.
How many people work for Intellia Therapeutics?
Latest data suggests 526 work at Intellia Therapeutics.
When does the fiscal year end for Intellia Therapeutics?
Intellia Therapeutics's fiscal year ends in December.
Where is Intellia Therapeutics based?
Intellia Therapeutics's address is: 40 Erie Street, Cambridge, MA, United States, 02139
What is Intellia Therapeutics's ISIN number?
Intellia Therapeutics's international securities identification number is: US45826J1051
What is Intellia Therapeutics's CUSIP number?
Intellia Therapeutics's Committee on Uniform Securities Identification Procedures number is: 45826J105

More guides on Finder

Ask a question

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site